Modulari-T pioneers cell therapy, reprogramming immune cells for potent cancer treatment with minimal side effects.

• MARCs (Modular Actuation Receptor Complexes) outshine CAR-T cells, offering double the tumor-clearing power.

• Modulari-T invites collaboration to bring hope, envisioning a world where every cell holds potential for a healthier future.


Have you ever dreamt of a world where sickness could be cured with precision, where cells could be reprogrammed to combat the deadliest diseases? Well, Modulari-T is turning that dream into a reality. Imagine a platform that teaches your immune system to not just fight but triumph over cancer. It's not science fiction; it's the incredible work of Modulari-T, a cell therapy company that's rewriting the rules of medical possibilities.

Scientifically speaking, Modulari-T is a pre-clinical stage biotechnology company focused on developing novel antigen receptor architecture for multiple immune cell types to overcome the challenges currently facing CAR-T therapy. 

Meet the minds behind Modulari-T:

Modulari-T is steered by a dynamic duo. David is the CEO and co-founder of Modulari-T. His expertise spans multiple areas and he is driven by a passion for pushing the boundaries of technology. During his PhD, he discovered how protein receptors form complex structures that allow them to alter cells’ behavior. He then took this knowledge and the novel technology that was developed to build Modulari-T.

Alongside him is Stephanie, the co-founder and COO at Modulari-T. As a PhD graduate from a bioengineering lab, her technical background lies within synthetic biology, advanced 3D cell culture systems, and biomaterials in the context of the cellular microenvironment. She is currently fascinated by the innovations in cell-based therapies, food products, and the scale-up of their manufacturing.

Cracking the code of Cell Therapy:

Modulari-T isn't your average startup; it's a powerhouse of scientists merging protein engineering, synthetic biology, and immunology. Their mission: teaching your immune system to dance with cancer and come out victorious. The secret sauce lies in optimized gene sequences introduced into immune cells, creating treatments twice as potent as chemotherapy but with a remarkable 90% reduction in harmful side effects.

In a world where cell therapy often falls short, leaving millions without hope, Modulari-T emerges as the beacon promising a brighter future for cancer patients and a supercharged cell therapy market exceeding $50 billion by the decade's end.

The marvel of MARCs:

The science behind Modulari-T revolves around MARCs or Modular Actuation Receptor Complexes. These synthetic genes mimic the modular architecture of immune receptors, enabling immune cells to recognize cancer antigens and mount a formidable response against tumors.

Compared to the widely-known CAR-T cells, MARCs boast double the tumor-clearing power while steering clear of immune exhaustion, ensuring a sustained and robust response. Oncology is just the beginning; the MARC platform's potential spans autoimmunity, neurology, regenerative medicine, and beyond.

The MARC platform isn't a solo act; it's a partnership waiting to happen. Modulari-T also invites collaboration, believing that together, they can bring hope to countless patients. The dream isn't just theirs; it's a shared vision of rewriting the medical narrative for a healthier, more resilient world.

This startup’s work isn't just groundbreaking science; it's a commitment to providing newfound hope. So, here's to Modulari-T, the architects of hope, shaping a world where every cell carries the potential for a healthier tomorrow.


Edited by Shruti Thapa